Your browser doesn't support javascript.
loading
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
Critchlow, Simone; Bullement, Ash; Crabb, Simon; Jones, Robert; Christoforou, Katerina; Amin, Amerah; Xiao, Ying; Kapetanakis, Venediktos; Benedict, Ágnes; Chang, Jane; Kearney, Mairead; Eccleston, Anthony.
Afiliación
  • Critchlow S; Delta Hat, Bramley House, Nottingham, NG10 3SX, UK.
  • Bullement A; Delta Hat, Bramley House, Nottingham, NG10 3SX, UK.
  • Crabb S; University of Southampton, University Road, Southampton, SO17 1BJ, UK.
  • Jones R; University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK.
  • Christoforou K; Merck Serono Ltd. 5 New Square, Feltham, TW14 8HA, UK, an affiliate of Merck KGaA.
  • Amin A; Merck Serono Ltd. 5 New Square, Feltham, TW14 8HA, UK, an affiliate of Merck KGaA.
  • Xiao Y; Evidera, 201 Talgarth Road, London, W6 8BJ, UK.
  • Kapetanakis V; Evidera, 201 Talgarth Road, London, W6 8BJ, UK.
  • Benedict Á; Evidera, Bocskai út 134-146, Budapest, 1113, Hungary.
  • Chang J; Pfizer, 235 E 42nd Street, New York, NY 10017, USA.
  • Kearney M; Merck Healthcare KGaA, Frankfurter Strasse 250, Darmstadt, 64293, Germany.
  • Eccleston A; Pfizer, Dorking Road, Tadworth, Surrey, KT20 7NS, UK.
Future Oncol ; 20(8): 459-470, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37529943
What is this article about? This study looked at the costs of avelumab when given as maintenance treatment for people in Scotland with advanced urothelial carcinoma, compared with the longer survival and other benefits that it provides. How was this done? Researchers estimated the costs and treatment benefits expected with avelumab using data from a clinical trial called JAVELIN Bladder 100, national databases, data from previously published studies and expert opinions. What were the results? Costs associated with using avelumab maintenance treatment for people with advanced urothelial carcinoma in Scotland were considered to be acceptable based on the benefits it provides. What do the results of the study mean? These results support the use of avelumab first-line maintenance as a standard treatment for people with advanced urothelial carcinoma in Scotland.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Future Oncol Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Future Oncol Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido